US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Diaprost Licenses its novel Theranostic Antibody, hu5A10, to Radiopharm Theranostics for Development in the Treatment and Diagnosis of Prostate Cancer.

The terms of an exclusive License Agreement, inclusive of an upfront payment and potential development and regulatory milestone payments over the life of the agreement, may exceed US$125 million.Diaprost announced today that it has agreed terms for an exclusive Licensing Agreement with Radiopharm Theranostics (RAD); an Australian based biotech startup, focused on building an innovative and differentiated pipeline of radiopharmaceutical products for both diagnostic and therapeutic uses. RAD has recently raised A$20 million to progress a portfolio of radiopharmaceutical assets that have the

Diaprost Announces Promising New Study for Patients with Metastatic PCa

Diaprost announced today a publication in the journal of Clinical Cancer Research on PSA-targeted Alpha-, Beta- and Positron Emitting Immuno-Theranostics in Murine Prostate Cancer Models and Non-Human Primates.The extensive preclinical study was conducted at Memorial Sloan Kettering Cancer Center (MSK) on Diaprost’s propriety antibody (hu5A10) targeting PSA. This rigorous preclinical evaluation of radiolabeled hu5A10-based compounds in prostate cancer (PCa) mouse models and non-human primates, establishes hu5A10 as a promising theranostic (therapy and diagnostic) agent that allows specific

Diaprost AB Acquires Rights to use of PSA Antibodies from Leading New York Cancer Center

Diaprost announced today that it has signed an exclusive license agreement with Memorial Sloan Kettering Cancer Center for IP related to the use of PSA antibodies for therapeutic and diagnostic purposes for prostate cancer. Diaprost is a private pharmaceutical research and development company based in Lund, Sweden and whose principle asset is h5A10, targeting PSA, a validated clinical biomarker.  The h5A10 antibody combined with the appropriate payload offers the potential for highly specific therapeutic and diagnostic products, for example as a therapeutic product to deliver cytotoxic

Diaprost announces Exercise of Option under the terms of its Research and Option Agreement with a leading Pharmaceutical company

Diaprost entered into an exclusive Research and Option Agreement with a Top 10 Pharmaceutical company strategic partner in October 2017.  Diaprost now announces that its strategic partner has exercised its option to acquire rights to its h11B6 antibody. An upfront payment and research funding has already been paid and an early-stage clinical trial has been initiated. In payments made prior to option exercise, Diaprost received $13M.  The option fee and potential future payments, including commercial milestones, for its h11B6 antibody for prostate cancer may be up to $90 million.  No

Study demonstrates the feasibility of targeting human kallikrein-related peptidase 2 (hK2) for detection and monitoring of prostate cancer

A new publication in Science Translational Medicine demonstrates that in vivo targeting of the enzyme human kallikrein-related peptidase 2 (hK2) is a powerful tool that can be used for detection of prostate cancer and monitoring treatment by quantifying the activity of the androgen receptor pathway.The authors of the article “Internalization of secreted antigen–targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis” (Thorek et al., Sci Transl Med . 2016 Nov 30;8(367))” hK2 in mouse

There are no items matching the current filter
There are no more items matching the current filter
Back to top